Aura Biosciences, Inc. (AURA) stock
AURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.14−0.01 (-0.14%)
Close on Nov 18, 2026Market cap $740.45MP/E –Yield –
Aura Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Aura Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$103.35M. For fiscal 2025 it was -$85.19M. The highest annual figure on record is -$25.09M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$85.19M | – |
| FY2024 | Dec 31, 2024 | -$81.06M | – |
| FY2023 | Dec 31, 2023 | -$64.56M | – |
| FY2022 | Dec 31, 2022 | -$55.70M | – |
| FY2021 | Dec 31, 2021 | -$34.54M | – |
| FY2020 | Dec 31, 2020 | -$25.09M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$32.52M | – |
| Q1 FY2026 | Mar 31, 2026 | -$30.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.65M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.19M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.81M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.25M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.61M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.65M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.54M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.70M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.84M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.37M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.82M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.70M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.80M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.91M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.26M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.16M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.89M | – |
See a number that looks wrong?